Bupropion
- Generic Name
- Bupropion
- Brand Names
- Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18ClNO
- CAS Number
- 34911-55-2
- Unique Ingredient Identifier
- 01ZG3TPX31
- Background
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...
- Indication
Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
- Associated Therapies
- Smoking, Cessation, Weight Loss
Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 580
- Registration Number
- NCT05351606
- Locations
- 🇰🇪
Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 180
- Registration Number
- NCT05205811
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
Effect of Smoking Cessation on Tuberculosis Treatment Outcomes
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 292
- Registration Number
- NCT04848246
- Locations
- 🇵🇰
Dow University of Health Sciences, Karachi, Sindh, Pakistan
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 9
- Registration Number
- NCT04757532
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
A Drug Interaction Study of Danicopan
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04709094
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
Drug-drug Interaction Study of KL1333 in Healthy Subjects
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 14
- Registration Number
- NCT04643249
- Locations
- 🇬🇧
Volunteer recruitment center Covance Leeds Covance Leeds, Leeds, United Kingdom
Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Joseph Valentino, MD
- Target Recruit Count
- 126
- Registration Number
- NCT04634071
- Locations
- 🇺🇸
Kings Daughters Medical Center - Ashland, Ashland, Kentucky, United States
🇺🇸Med Center Health, Bowling Green, Kentucky, United States
🇺🇸University Of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
Relapse Prevention in Stimulant Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT04553263
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04464577
- Locations
- 🇺🇸
Local Institution, Salt Lake City, Utah, United States
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04457180
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.